伯氨喹与亚甲蓝预防恶性疟原虫传播在馬里的疗效与安全性:一项2期、单盲、随机对照试验
在馬里G6PD正常、配子体血症的5-50岁男性中,将单剂伯氨喹0.25 mg/kg加入磺胺多辛-乙胺嘧啶+阿莫地喹,或将亚甲蓝15 mg/kg/天连用3天加入双氢青蒿素-哌喹,均能显著降低第2天蚊虫感染性;两组血红蛋白变化与各自对照相似,不良事件组间相似。
要点
- 单剂伯氨喹0.25 mg/kg或亚甲蓝15 mg/kg/天×3天可大幅降低恶性疟原虫对蚊媒的传播。
- 伯氨喹组第2天蚊媒感染性中位下降100%,显著优于单用磺胺多辛-乙胺嘧啶+阿莫地喹。
- 亚甲蓝组第2天蚊媒感染性中位下降100%,显著优于单用双氢青蒿素-哌喹。
核心结论
- 在磺胺多辛-乙胺嘧啶+阿莫地喹基础上加单剂伯氨喹0.25 mg/kg,或在双氢青蒿素-哌喹基础上加亚甲蓝15 mg/kg/天连用3天,对阻止恶性疟原虫传播高度有效,且两药耐受性良好。
研究设计与样本
- 2期、单盲、随机对照试验,在馬里巴马科大学疟疾研究与培训中心临床研究中心进行。
- 纳入5-50岁无症状恶性疟原虫感染者,G6PD正常且血涂片检出配子体的男性参与者。
- 按1:1:1:1区组随机(区组大小8,密封信封设计)分为四组,每组20人,共80人。
- 四组分别为磺胺多辛-乙胺嘧啶+阿莫地喹、磺胺多辛-乙胺嘧啶+阿莫地喹+单剂伯氨喹0.25 mg/kg、双氢青蒿素-哌喹、双氢青蒿素-哌喹+亚甲蓝15 mg/kg/天连用3天。
- 主要疗效终点为治疗前和治疗后至少一次感染性测量的所有感染患者中,治疗第2天和第7天经膜喂养评估的个体内蚊媒感染性百分比变化中位数。
主要发现
- 基线时有感染性的参与者为54/80(68%)。
- 伯氨喹组(n=19)第2天蚊媒感染性个体内中位下降100%(IQR 100至100),优于单用磺胺多辛-乙胺嘧啶+阿莫地喹组(n=12;-10.2%,IQR -143.9至56.6;p<0.0001)。
- 亚甲蓝组(n=11)第2天蚊媒感染性个体内中位下降100%(IQR 100至100),优于单用双氢青蒿素-哌喹组(n=12;-6.0%,IQR -126.1至86.9;p<0.0001)。
- 配子体杀灭药组与各自对照组之间血红蛋白变化相似。
- 排除蓝色尿液后,不良事件在所有组间相似;80名参与者中59人(74%)共发生162例不良事件,其中145例(90%)为轻度。
关键数值与推荐
- 伯氨喹组第2天蚊媒感染性中位下降100%(IQR 100至100),对照单用磺胺多辛-乙胺嘧啶+阿莫地喹组为-10.2%(IQR -143.9至56.6),p<0.0001。
- 亚甲蓝组第2天蚊媒感染性中位下降100%(IQR 100至100),对照单用双氢青蒿素-哌喹组为-6.0%(IQR -126.1至86.9),p<0.0001。
- 不良事件总体:59/80(74%)参与者发生162例,其中145/162(90%)为轻度。
临床怎么用
- 在G6PD正常的配子体血症男性中,可考虑在磺胺多辛-乙胺嘧啶+阿莫地喹基础上加单剂伯氨喹0.25 mg/kg以阻断传播。
- 在G6PD正常的配子体血症男性中,可考虑在双氢青蒿素-哌喹基础上加亚甲蓝15 mg/kg/天连用3天以阻断传播。
- 原文未据此给出指南推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primaquine and methylene blue are gametocytocidal compounds that could prevent Plasmodium falciparum transmission to mosquitoes. We aimed to assess the efficacy and safety of primaquine and methylene blue in preventing human to mosquito transmission of P falciparum among glucose-6-phosphate dehydrogenase (G6PD)-normal, gametocytaemic male participants. METHODS: This was a phase 2, single-blind, randomised controlled trial done at the Clinical Research Centre of the Malaria Research and Training Centre (MRTC) of the University of Bamako (Bamako, Mali). We enrolled male participants aged 5-50 years with asymptomatic P falciparum malaria. G6PD-normal participants with gametocytes detected by blood smear were randomised 1:1:1:1 in block sizes of eight, using a sealed-envelope design, to receive either sulfadoxine-pyrimethamine and amodiaquine, sulfadoxine-pyrimethamine and amodiaquine plus a single dose of 0·25 mg/kg primaquine, dihydroartemisinin-piperaquine, or dihydroartemisinin-piperaquine plus 15 mg/kg per day methylene blue for 3 days. Laboratory staff, investigators, and insectary technicians were masked to the treatment group and gametocyte density of study participants. The study pharmacist and treating physician were not masked. Participants could request unmasking. The primary efficacy endpoint, analysed in all infected patients with at least one infectivity measure before and after treatment, was median within-person percentage change in mosquito infectivity 2 and 7 days after treatment, assessed by membrane feeding. This study is registered with ClinicalTrials.gov, number NCT02831023. FINDINGS: Between June 27, 2016, and Nov 1, 2016, 80 participants were enrolled and assigned to the sulfadoxine-pyrimethamine and amodiaquine (n=20), sulfadoxine-pyrimethamine and amodiaquine plus primaquine (n=20), dihydroartemisinin-piperaquine (n=20), or dihydroartemisinin-piperaquine plus methylene blue (n=20) groups. Among participants infectious at baseline (54 [68%] of 80), those in the sulfadoxine-pyrimethamine and amodiaquine plus primaquine group (n=19) had a median 100% (IQR 100 to 100) within-person reduction in mosquito infectivity on day 2, a larger reduction than was noted with sulfadoxine-pyrimethamine and amodiaquine alone (n=12; -10·2%, IQR -143·9 to 56·6; p<0·0001). The dihydroartemisinin-piperaquine plus methylene blue (n=11) group had a median 100% (IQR 100 to 100) within-person reduction in mosquito infectivity on day 2, a larger reduction than was noted with dihydroartemisinin-piperaquine alone (n=12; -6·0%, IQR -126·1 to 86·9; p<0·0001). Haemoglobin changes were similar between gametocytocidal arms and their respective controls. After exclusion of blue urine, adverse events were similar across all groups (59 [74%] of 80 participants had 162 adverse events overall, 145 [90%] of which were mild). INTERPRETATION: Adding a single dose of 0·25 mg/kg primaquine to sulfadoxine-pyrimethamine and amodiaquine or 3 days of 15 mg/kg per day methylene blue to dihydroartemisinin-piperaquine was highly efficacious for preventing P falciparum transmission. Both primaquine and methylene blue were well tolerated. FUNDING: Bill & Melinda Gates Foundation, European Research Council.
引用
- Dicko A, Roh ME, Diawara H, et al. Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. Lancet Infect Dis. 2018. PMID: 29422384. doi:10.1016/S1473-3099(18)30044-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。